Enhanced dopamine transporter function in striatum during nicotine withdrawal

Synapse

Volumn 65, Issue 2, 2011, Pages 91-98

  Hadjiconstantinou, Maria ^a   Duchemin, Anne Marie ^a   Zhang, Hailing ^a   Neff, Norton H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

DA overflow; DA uptake; DAT mRNA; Striatum; Substantia nigra pars compacta; Ventral tegmental area

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; MESSENGER RNA; NICOTINE; NOMIFENSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG WITHDRAWAL; EX VIVO STUDY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; SYNAPTOSOME; VENTRAL TEGMENTUM;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; MALE; MICE; NICOTINE; NICOTINIC AGONISTS; RNA, MESSENGER; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 78650009805     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20820     Document Type: Article

References (51)

1. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. 2001. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11: 449-455.
2. Broom SL, Yamamoto BK. 2005. Effects of subchronic methamphetamine exposure on basal dopamine and stress-induced dopamine release in the nucleus accumbens shell of rats. Psychopharmacology 181: 467-476.
3. Brogden RN, Heel RC, Speight TM, Avery GS. 1979. Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18: 1-24.
4. Carboni E, Bortone L, Giua C, Di Chiara G. 2000. Dissociation of physical signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend 58: 93-102.
5. Claye LH, Akunne HC, Duff-Davis M, DeMatto S, Soliman KFA. 1995. Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration. Mol Neurobiol 11: 55-66.
6. Copeland BJ, Vogelsberg V, Neff NH, Hadjiconstantinou M. 1996. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J Pharmacol Exp Ther 277: 1527-1532.
7. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. 2003. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168: 347-358.
8. Drew AE, Derbez AE, Werling LL. 2000. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 38: 10-16.
9. Drew AE, Werling LL. 2001. Protein kinase C regulation of dopamine transporter initiated by nicotinic receptor activation in slices of rat prefrontal cortex. J Neurochem 77: 839-848.
10. Duchemin A-M, Zhang H, Neff NH, Hadjiconstantinou M. 2009. Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal. Neurosci Lett 467: 182-186.
11. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. 1998. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393: 76-79.
12. Eriksen J, Jorgensen TN, Gether U. 2010. Regulation of dopamine transporter function by protein-protein interactions: New discoveries and methodological challenges. J Neurochem 113: 27-41.
13. Ferrari R, Le Novere N, Picciotto MR, Changeux JP, Zoli M. 2001. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 15: 1810-1818.
14. Gäddnäss H, Petteri Piepponen T, Ahtee L. 2002. Mecamylamine decreases accumbal dopamine output in mice treated chronically with nicotine. Neurosci Lett 330: 219-222.
15. Goettl VM, Zhang H, Burrows AC, Wemlinger TA, Neff NH, Hadjiconstantinou M. 2003. GM1 enhances dopaminergic marker in the brain of aged rats. Exptl Neurol 183: 665-672.
16. Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff MH. 1994. Enhanced MPTP neurotoxicity after treatment with isoflurophosphate or cholinergic agonists. J Pharmacol Exp Ther 270: 639-644.
17. Hart C, Ksir C. 1996. Nicotine effects on dopamine clearance in rat nucleus accumbens. J Neurochem 66: 216-221.
18. Hildebrandt BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. 1998. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779: 214-225.
19. Hildebrandt BE, Panagis G, Svensson TH, Nomikos GG. 1999. Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: Role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21: 560-574.
20. Isola R, Vogelberg V, Wemlinger TA, Neff NH, Hadjiconstantinou M. 1999. Nicotine abstinence in the mouse. Brain Res 850: 189-196.
21. Janhunen S, Ahtee L. 2007. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: Implications for drug development. Neurosci Biobehav Rev 31: 287-314.
22. Koff JM, Shuster L, Miller LG. 1994. Chronic cocaine administration is associated with behavioral senstitization and time-dependent changes in striatal dopamine transporter binding. J Pharmacol Exp Ther 268: 277-282.
23. Li L-B, Chen N, Ramamoorthy S, Chi L, Ciu X-N, Wang LC, Reith MEA. 2004a. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 279: 21012-21020.
24. Li S, Kim KY, Kim JH, Kim JH, Park MS, Bahk JY, Kim MO. 2004b. Chronic nicotine and smoking treatment increase dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 363: 29-32.
25. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB. 1992. Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43: 779-784.
26. Mateo Y, Lack CM, Morgan D, Roberts DCS, Jones SR. 2005. Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self-administration and deprivation. Neuropsychopharmacology 30: 1455-1463.
27. Meiergerd SM, Schenk Jo. 1994. Striatal transporter for dopamine: Catechol structure-activity studied and susceptibility to chemical modification. J Neurochem 62: 998-1008.
28. Meiergerd SM, McElvain JS, Schenk JO. 1994. Effects of cocaine and repeated cocaine followed by withdrawal. Alterations of dopaminergic transporter turnover with no changes in kinetics of substrate recognition. Biochem Pharmacol 47: 1627-1634.
29. Middleton LS, Cass WA, Dwoskin LP. 2004. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Ther 308: 367-377.
30. Middleton LS, Apparsundaram S, King-Pospisil KA, Dwoskin LP. 2007. Nicotine increases dopamine transporter function in striatum through a trafficking-independent mechanism. Eur J Pharmacol 554: 128-136.
31. Mortensen OV, Amara GA. 2003. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 479: 159-170.
32. Ng JP, Hubert GW, Justice JB Jr. 1991. Increased stimulated release and uptake of dopamine in nucleus accumbens after repeated cocaine administration as measured by in vivo voltametry. J Neurochem 56: 1485-1492.
33. Ohyama K, Sogawa C, Sogawa N, Morita K, Dohi T, Kitayama S. 2010. Nicotine stimulates transcriptional activity of the human dopamine transporter gene. Neurosci Lett 471: 34-37.
34. Parsons LH, Smith AD, Justice JBJr. 1991. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9: 60-65.
35. Paterson NE, Balfour DJ, Markou A. 2007. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25: 3099-3118.
36. Paxinos G, Franklin BL. 2001. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
37. Povlock SL, Amara SG. 1997. The structure and function of norepinephrine, dopamine and serotonin transporters. In: Reith MA, editor. Neurotransmitter transporters. New Jersey: Humana Press. p 1-28.
38. Rada P, Jensen K, Hoebel BG. 2001. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology 157: 105-110.
39. Rahman S, Zhang J, Engleman EA, Corrigall WA. 2004. Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: A microdialysis study. Neuroscience 129: 415-424.
40. Rossetti ZL, Hmaidan Y, Gessa GL. 1992. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221: 227-234.
41. Schmitz Y, Schmauss C, Sulzer D. 2002. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J Neurosci 22: 8002-8009.
42. Shepard JD, Chuang DT, Shaham Y, Morales M. 2006. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal pathways of the rat. Psychopharmacology 185: 505-513.
43. Shram MJ, Siu EC, Li Z, Tyndale RF, Lee AD. 2008. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology 198: 181-190.
44. Stoker AK, Semenova S, Markou A. 2008. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57Bl/6j and BALB/cByj mice. Neuropharmacology 54: 1223-1232.
45. Suzuki T, Ise Y, Tsuda M, Maeda J, Misawa M. 1996. Mecamylamine-precipitated nicotine withdrawal aversion in rats. Eur J Pharmacol 314: 282-284.
46. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG. 2003a. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains for the functional expression of the transporter. J Biol Chem 278: 2731-2739.
47. Torres GE, Gainetdinov RR, Caron MG. 2003b. Plasma membrane monoamine transporters: Structure, regulation and function. Nat Rev Neurosci 4: 13-25.
48. --dependent neurotransmitter transporters: Drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 92: 21-55.
49. Zahniser NR, Sorkin A. 2009. Trafficking of the dopamine transporters in psychostimulant actions. Semin Cell Dev Biol 20: 411-417.
50. Zhu J, Reith ME. 2008. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets 7: 393-409.
51. 3H]Dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Ther 328: 931-939.